ProCE Banner Activity

ECOG-ACRIN E2906: Maintenance Decitabine After Response to Intensive Therapy in Older AML Patients

Slideset Download
Conference Coverage
Decitabine maintenance showed improved survival outcomes compared with observation alone, especially in FLT3-ITD–negative patients.

Released: December 20, 2019

Expiration: December 18, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company